STAT+: Johnson & Johnson to buy Shockwave Medical for $13.1 billion

Johnson & Johnson on Friday announced it would acquire heart device firm Shockwave Medical for $13.1 billion. It’s J&J’s second major deal in the cardiovascular space in two years, following its 2022 purchase of Abiomed for $16.6 billion. 

Shockwave Medical’s device works to break down calcified plaque in the coronary and peripheral arteries using sonic pressure waves — a treatment called intravascular lithotripsy. The founders based the technology on lithotripsy to remove kidney stones, a therapy that has been in use since the 1980s. According to a press statement, Shockwave has treated 400,000 patients with this method globally. The company earned its first clearance from the Food and Drug Administration in 2016, and went public in 2019 at a share price of $17. 

“As part of a larger, more diverse organization, with broad expertise and a core focus on improving patient outcomes, we are confident we will be able to further solidify IVL as the global standard of care for patients,” said Shockwave Medical CEO Doug Godshall in a statement. 

Continue to STAT+ to read the full story…

Read Original Article: STAT+: Johnson & Johnson to buy Shockwave Medical for $13.1 billion »